010-84476011
环球医学>> 医学新闻>> 政策法规>>正文内容
政策法规

FDA积极支持和批准新的治疗肥胖症的药物和治疗方案

来源:环球医学编译    时间:2012年07月20日    点击数:    5星

7月20日消息-环球医学据悉,肥胖保健连续体(OCC)的成员对美国FDA在确保用于治疗超过9300万的美国肥胖患者治疗方案的安全问题的持续、积极主动的做法表示感谢。

7月17日,Qsymia(芬特明和托吡酯)获美国FDA批准,标志着在不到一个月的时间内美国FDA第二次批准一种新的治疗肥胖症的药物。在六月下旬,Belviq(lorcaserinHCI)也被FDA批准。

肥胖协会(TOS)的主席帕特里克•奥尼尔博士说,“通过批准另一种药物,将有助于医疗专业人员更有效地治疗肥胖症,FDA继续向我们展示了他们治疗肥胖症的认真态度。由于导致肥胖的原因很多,没有哪种单一药物能适合每一个人。这一认识是朝正确方向迈出的一大步,但是,我们必须坚持致力于开发更多安全、有效和易于接受的治疗方法。

肥胖行动联盟(OAC)的总裁兼首席执行官Joe Nadglowski 先生说,“随着这些新的治疗方法的审批,我们强烈鼓励肥胖患者与他们的医疗专业人员讨论他们的体重问题。很多时候,由于缺乏治疗方案,个人会逃避谈论自己的体重问题。由于FDA最近致力于增加新的治疗方案,美国人现在已拥有更多可用的工具来解决他们的体重和健康问题。(环球医学)
 

原文

                   FDA commended by the Obesity Care Continuum

 

      Singapore: Members of the Obesity Care Continuum (OCC) commended the US FDA for their continued proactive approach to ensuring safe obesity treatment options for the more than 93 million Americans affected by the disease.

 

       July 17 marked the second time in less than a month that the FDA approved a new medication, Qsymia (phentermine and topiramate), for the treatment of obesity. In late June, Belviq (lorcaserin HCl) was also approved by the FDA.

 

       Dr Patrick O'Neil, president, The Obesity Society (TOS), said that, "By approving another medication that will help healthcare professionals treat this disease more effectively, the FDA continues to show us that they are treating obesity seriously. Since obesity can arise from many causes, no single medication will work for everyone. This is a great step in the right direction, but, we must maintain our focus of developing even more treatments that are safe, effective, and accessible."

 

       Mr Joe Nadglowski, president and CEO, Obesity Action Coalition (OAC), said that, "With the approval of these new treatments, we strongly encourage individuals affected by obesity to have the discussion of weight with their healthcare professional. Quite often, individuals affected avoid the conversation of weight due to a lack of treatment options. Thanks to the FDA's recent movement toward increasing options, Americans will now have more tools in the toolbox to address their weight and health."

          相关链接http://www.biospectrumasia.com/biospectrum/regulatory/2412/fda-commended-obesity-care-continuum

        版权声明:本文系环球医学独家稿件,版权为环球医学所有。欢迎转载,请务必注明出处(环球医学网),否则必将追究法律责任。

评价此内容
 我要打分

现在注册

联系我们

最新会议

    [err:标签'新首页会议列表标签'查询数据库时出现异常。有关错误的完整说明,请到后台日志管理中查看“异常记录”]